Business
Immunome Announces Pricing of Upsized Initial Public Offering
EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and
About this update from Immunome, Inc.
[{"type":"text","content":" EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated, today announced the pricing of its initial public offering. The offering was upsized to 3,250,000 shares of common stock at a public offering price of $12.00 per share. All of the shares are being offered by Immunome. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $39.0 million. Additionally, Immunome has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Capital Market on October 2, 2020, under the ticker symbol “IMNM.” The offering is expected to close on October 6, 2020, subject to the satisfaction of customary closing conditions.\n\nLadenburg Thalmann & Co. Inc. and Chardan are acting as book-running managers for the offering.\n\nA registration statement relating to these securities has been declared effective by the Securities in Exchange Commission on October 1, 2020. The offering will be made only by means of a prospectus. When available, copy of the final prospectus relating to the offering may be obtained from Ladenburg Thalmann & Co. Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, or by calling (212) 409-2000, or by emailing [email protected] or Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004, or by calling (646) 465-9001.\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n\nAbout Immunome, Inc.\n\nImmunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s propr...